The purpose of this study was to test a modification of antipyrine test in calves. The experiment was carried out on 10 calves (bulls of black and white breed). Each subject received on days 10 and 20 of life. respectively. 15 mg.kg· l body mass of antipyrine as an intravenous bolus injection. followed by its oral administration "in substantia" in gelatin capsules 48 hours later. The concentrations of antipyrine in their saliva were repeatedly determined. Pharmacokinetics of antipyrine was followed in each subject (according to a one-compartment open model) using five modifications: a complete study (A). and four abbreviated studies. i.e using the 4. 8 and 12 h saliva collection times (B). the 4 and 8 h collection times (C), further the 4 and 12 h (D). and finally the 8 and 12 h saliva collection times (E). Correlational analysis was used to compare the substance kinetics from the complete set of data obtained from all saliva collections with the results using each of the abbreviated approaches.
In conclusion. we demonstrated that antipyrine pharmacokinetic parameters in calves can be determined with reasonable precision using a two-point or three-point saliva sampling procedure following a single oral dose. Moreover. this simplified sampling method can be used for largescale investigations. where estimation of hepatic mixed function oxygenases (MFO) activity is needed.
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Antipyrine (Phenazone) has been widely used as a model substrate for cytochrome P-450 dependent metabolism (Danhof and Teunissen 1984; Poulsen and Loft 1988; Loft 1990) . Antipyrine is eliminated primarily via hepatic metabolism, has a low intrinsic hepatic clearance, and is negligibly bound to tissue and plasma proteins (D a n h 0 f and B re i me r 1989; Hartleb 1991; Konig and Cantilena 1994) . Measurements of half-life and metabolic clearance of antipyrine have therefore been used to assess the drug-metabolizing activity of the liver in man and animals and its modification by genetic and multiple environmental factors (Danhof and Teunisen 1984; Depelchin etal. 1988; Loft 1990; Hartleb 1991) .
Assessment of antipyrine pharmacokinetics can be made through measurement of its plasma or saliva concentrations (Harman et al. 1987; Loft et al. 1988; Si vagnanam et al. 1988; Vital-Durand et al. 1988; Loft et al. 1991) . Discussions as to which of these biological fluids should be used have focused on the accuracy or convenience of each method (Scavone et al. 1988; Svensson 1988; Janus et al. 1991) .
Estimation of pharmacokinetic parameters for antipyrine has traditionally required collection of up to ten or more blood samples during the 24 hours following administration ofa single dose (Scavone et al. 1988; Hartleb 1991; Konig and Cantilena 1994) . If antipyrine kinetics could be assessed with reasonable precision using less laborious blood sampling procedures, the usefulness of this test might be enhanced (Sca vone et al. 1988; Sivaganam et al. 1988; Fabbri et al. 1991). In domestic animals (especially in the neonatal period) relatively little is known about pharmacokinetics of antipyrine (D e pe I chi n et. al. 1988) . Our previous experiment (J an u s et al. 1991) indicated that the measurement of antipyrine elimination rate from saliva after intravenous its administration can be used to assess the activity of hepatic monooxygenase system in calves.
The purpose of this study is further modification of the antipyrine test in calves. Based on antipyrine pharmacokinetic analysis after its i.ntravenous and oral administration, we attempt to answer the following question: are the "noninvasive" variants of the antipyrine test (oral administration of the drug, and determination of changes in salivary concentrations of antipyrine) suitable for a precise determination of the hepatic biotransformation rate (activity of mixed function oxygenases [MFa] system) in calves in their neonatal period? Therefore we also evaluated the suitability of several abbreviated methods for determination pharmacokinetics of antipyrine in calves.
Materials and Methods

Animals
The experiment was carried out on 10 calves (bulls of black and white breed). The animals were kept in single cages and fed in a common way. Before starting the experiment the calves were subjected to the catheterization venajugularis externa. During the experiment the calves did not obtain any pharmacological substances that could interfere with antipyrine.
Experimental procedures
Each subject was given IS mg.kg-' body mass of antipyrine (Phenazone -Sigma, VSA.) on day 10 and 20 after birth as intravenous bolus injection (10% aqueous sterile solution) followed 48 hours later by an i. v. administration of antipyrine "in substantia" in a gelatin capsule. Saliva samples (about 5 ml) were collected as described previously (J a nus et al. 1991), i.e. at ,,0", and 3, 4, 5, 6, 7, 8, 9, 10, 12, 18 and 24 hours after i. v. or oral drug administration. Samples were stored at -20°C until analysed.
The concentration of antipyrine in saliva was determined by the spectrophotometric method according to Brodie et al. (1979) .
The pharmacokinetics of antipyrine was calculated according to a one compartment open model, using results obtained in the slow phase (~) of drug elimination (Loft 1990; Hartleb 199\) . In these studies ke, (elimination coefficient for antipyrine) and Co (initial concentration) were calculated by the least squares method from the curve of antipyrine concentration in plasma (C) in relation to time (t). Biological half-life of antipyrine (10.5) was calculated from the following relationship: t 0.5 = 0.6931k",. The bioavailability (F) of antipyrine after oral administration was calculated according to the following formulas: F = AVCo/AVC i . v .; in which AVC or and AVCi.v. are the areas underthe saliva concentration versus time curves (calculated according to the log-linear trapezoidal rule) extrapolated to infinity following oral and intravenous administrations, respectively.
Pharmacokinetics of antipyrine for each subject were determined in the following five ways:
A) complete study, i.e. using all saliva samplings, B) using the 4, 8 and 12 h sampling points only C) using the 4 and 8 h sampling points only D) using the 4 and 12 h sampling points only E) using the 8 and 12 h sampling points only.
Correlational analysis was used to compare kinetic results from the complete set of data (sampling times) with results using each of the abbreviated approaches.
Statistics
For statistical analysis the paired Student' t·test was used. Statistical and pharmacokinetics calculations were performed on an 486 DXl40 computer system.
Results and Discussion
The mean pharmacokinetic data for antipyrine obtained from measurements in saliva are presented in Tables 1 and 2 . Correlation coefficients between the complete and abbreviated studies for half-life and metabolic' clearance of antipyrine are presented in Table 3 . Based on the complete kinetics studies, mean kinetic variables for antipyrine were as follows: halflife -12.0 ± 01.12 h, metabolic clearance -0.75±0.06 ml/minlkg (1O-day-old calves) and 10.00 ± 0.89 h; 0.80 ± 0.07 mllminlkg (20-day-old calves), see Tables 1 and 2 . Mean values determined by each of the four abbreviated studies were very similar, and values for abbreviated vs. complete studies were highly significantly correlated (Table 3) . Table I Pharmacokinetic parameters of antipyrine in saliva after intravenous and per os administration (10 day-old calves) (n = 10, x ± SD) to.5 -half-life; k -elimination coefficient; CIA -metabolic clearance; AVC -area under curve; F -bioavailability Except for man, only few comparative data are available on the pharmacokinetics of antipyrine after intravenous and oral administration. In general, it is difficult to determine whether pharmacokinetics data obtained in calves can be extrapolated directly to man and laboratory animals (Depelchin et al. 1988; Jan us et al. 1991) .
The results obtained in the present study indicate that the pharmacokinetics of antipyrine in saliva of calves after intravenous and oral administration are very similar. This observation is in agreement with data presented by Eichelbaum et al. (1982) . Likewise, Danhof et al. (1982) reported very similar values of metabolic clearance of antipyrine in man after intravenous and oral administration. They proved good correlation between the V d, t 0.5 and CIA values that were independent of the route of antipyrine administration and the biological fluid (plasma, saliva) in which the concentration of the drug was detennined. The authors found that independently of the route of antipyrine administration, about 65% of the drug dose was excreted in urine as its metabolites. In both cases only 4% administered dose was excreted in urine as unchanged antipyrine. Andreasen and Vesell (1974) reported that in man antipyrine is almost completely absorbed from the gastrointestinal tract (bioavailability: F » 1) and did not exhibit a detectable "first-pass" phenomenon; therefore it is possibly a precise determination of V d and CIA values after oral administration.
Bioavailability of antipyrine in calves after its administration in gelatin capsules amounted toO.96 ± 0.03 in 10-day-old, and 0.97 ± 0.04 in 20-day-oldcalves. Similar results were found in man by Eichelbaum eta1. (1982) , Paradowski (1987 )and Danhof eta1. (1982 . The latter authors administered antipyrine orally as an aqueous solution and in gelatin capsules, and demonstrated that an aqueous solution of antipyrine is fully bioavailable (F = 1.05 ± 0.11), whereas when given as capsules its absorption from the gastrointestinal tract was not always complete (F < 0.9). A different opinion is presented by WeI c h et a1. (1975) . They demonstrated that when antipyrine was given in gelatin capsules, its bioavailability was practically always very high. They also found that when antipyrine was administered orally as an aqueous solution, its salivary concentration did not reflect the plasma concentration untill h after administration. Svensson (1988) (1975) . They stated that the "true" elimination phase of antipyrine from saliva (after oral administration) begins 120 min after the drug ingestion. In our previous experiment, the time of antipyrine absorption from the gastrointestinal tract of the examined calves was longer ( X t max = 150 min). The differences observed may be due to species differences or due to the fact that antipyrine in young calves was absorbed more slowly than in older or adult animals. Attempts to establish the efficacy of simplified methods for determination of the pharmacokinetics of antipyrine have been previously reported in man. Dos sing et a1. (1982) calculated the antipyrine clearance based on a single sample only. This method, however, requires that the vol ume of distribution be either simply assumed or calculated from equations relating total body water to age, body mass or gender (Pilsgaard and Poulsen 1984) . Dan ho f et a1. (1982) stated that the one-sample test is especially applicable in investigations in which each subject serves as his own control and where no alterations in volume of distribution are expected. On the other hand, the test cannot be used in studies in which a measurement ofV d from the antipyrine data is needed (Dossing et a1. 1982) .
Determination of the antipyrine clearance by the two or three-point saliva collection procedure in calves is reliable and simpler than multiple sampling. The optimal time interval from antipyrine administration to saliva sampling for its concentration measurement in the abbreviated studies was 4, 8 and 12 hours. This observation is in agreement with data presented by Scavone et a1. (1988) in man. Also Farrell and Zaluzny (1984) found good correlation in antipyrine clearance values between two-point and six-point studies.
In conclusion, we demonstrated a good agreement of antipyrine pharmacokinetic parameters calculated on the basis of changes in its sali\a concentration after intravenous and oral administration. Furthermore, almost a 100% bioavailability of antipyrine in the examined animals shows that it is possible to evaluate precisely the hepatic biotransformation rate in healthy calves in the neonatal period using a noninvasive modification of the antipyrine test. The test consists of antipyrine administration in a gelatin capsule and later determination of changes in its saliva concentration. We have also demonstrated that antipyrine pharmacokinetic parameters can be measured with reasonable precision using a simplified two-point or three-point saliva sampling procedure following a single oral dose.
Vyhodnoceni jednoducheho antipyrinoveho testu u tel at
CHern studie bylo overit modifikaci antipyrinoveho testu u telat. Pokus byl proveden na 10 telatech (b)'cci cemobileho plemene). Kazdemu jedinci byl 10. a 20. dne po narozeni podan iv. antipyrin v davce 15 mg.kg·\ zive hmotnosti. Za 48 h jim byl antipyrin podan v zelatinovych kapslich. Pote byla merena koncentrace antipyrinu ve slinach telat. leho farmakodynamika byla sledovana za pouziti 5 schemat odberu vzorku slin: kompletni studie (A), za pouziti vzorku odebranych po 4,8 a 12 h (B), dale po 4 a 8 h (C), po 4 a 12 h (D), a konecne po 8 a 12 h (E). Korelacni analyza byla pouzita k porovnani vysledku kinetiky z kompletnich udaju a ze zknkenych studii B-E. Na zaklade kompletni kineticke studie byly zjiSteny nasledujici parametry pro antipyrin:
polocas 12.00 ± 1.12 h, metabolicka clearance 0.75 ± 0.06 ml.min. kg ( 
